Basal cell carcinoma - Mate Pukupuku Pūtau Basal
☆ AI Dermatology — Free Service
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
I te 2022 Stiftung Warentest hua mai i Tiamana, he iti noa iho te pai o nga kaihoko ki a ModelDerm i nga korero mo te waea rongoa utu.
Ko te mate kiri o te ihu i te tangata kaumātua ka kitea he Mate Pukupuku Pūtau Basal (Basal cell carcinoma). Ko te ihu te wāhi ka kitea mō tēnei momo mate pukupuku kiri.
Mate Pukupuku Pūtau Basal (Basal cell carcinoma) ka puta mai i te taitapa kopikopiko me ngā whewhe.
Mate Pūkupuku Pūtau Basal (Basal cell carcinoma) ka pohehe he kiritona.
relevance score : -100.0%
ReferencesKo Basal cell carcinoma (BCC) te momo tino mate pukupuku kiri. Ko te whiti o te rā te take matua. Tata ki te katoa o ngā kēhi BCC e whakaatu ana i te kaha o te tohu Hedgehog i roto i te tātaritanga ngota. He rerekē ngā maimoatanga e wātea ana, me te whiriwhiri i runga i te tūpono, ka hoki mai anō, te hiranga o te tiaki kiko, te hiahia o te manawanui, me te nui o te mate.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Ko te Basal cell carcinomas te momo mate pukupuku kiri e tino kitea ana i roto i ngā pakeke, ā, ka pā ki te hunga 50 tau neke atu. Kei te piki haere te nama o tēnei mate puta noa i te ao, ā, ko te nuinga o ngā take he pānga ki te māra o te rā. He āhuatanga ētahi e whakapiki ake i te tūpono o te tangata ki te whakawhanake i ēnei mate i te tamarikitanga. He rerekē te āhua o te Basal cell carcinomas, ā, ka puta i ngā reinga papapapa, nodular rānei, ā, ka taea te rongoa i ngā mea whānui ake, engari e hiahiatia ana he kōrero ki ngā rōpū rongoā motuhake. Ko te matapae he whakawhirinaki ki te huringa o te mate, ki tōna kaha ki te tukino i ngā kiko tata. Ko te pokanga te maimoatanga paerewa mō te nuinga o ngā keehi, me te whakarite kia tika te tango me te iti o te tūpono kia hoki mai anō. Ka taea e ngā tikanga whakaeke iti ake te rongoa i ngā whiu papa.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
Ko te maimoatanga tuatahi mō te BCC he pokanga. Mō te BCC mōrearea nui, ka hoki mai anō rānei, i ngā wāhi tino nui, ka tūtohuhia he pokanga micrographically controlled. Ko ngā turoro me te BCC iti mōrearea ka whakaaro pea ki ngā maimoatanga kaupapa, ki ngā tikanga kino rānei. He pai te mahi whakamāramatanga Photodynamic mō ngā BCC nodular papapapa me te iti mōrearea. Mō te BCC matatau o te rohe, he metastatic rānei, ka tūtohuhia ngā aukati Hedgehog (vismodegib, sonidegib). Mēnā kei te haere tonu te mate, te kāore rānei ki te aukati Hedgehog, ka taea te whakaaro ki te whakamāramatanga mate me te anti‑PD1 antibody (cemiplimab). He pai te mahi irirangi mō ngā turoro kāore e taea te mahi pokanga, i ngā turoro pakeke. Ka taea te whakaaro ki te whakamāramatanga hiko ki te kore te pokanga, te whakamāramatanga irirangi rānei.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.
#Dermoscopy
#Skin biopsy
#Mohs surgery